Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Abstract Background AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results from two single-arm, phase II adjuvant trials (Trial 3 and Trial 5) wit...

Full description

Bibliographic Details
Main Authors: Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki, Andrzej Mackiewicz
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Immunotherapy
Genetic melanoma vaccine
Long-term survivals
Phase II clinical trials
Re-induction
Online Access:http://link.springer.com/article/10.1186/s40425-018-0456-1

Internet

http://link.springer.com/article/10.1186/s40425-018-0456-1

Similar Items